<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05125042</url>
  </required_header>
  <id_info>
    <org_study_id>CAAF</org_study_id>
    <nct_id>NCT05125042</nct_id>
  </id_info>
  <brief_title>Catgut Embedding in Acupoints on Treating Persistent Atrial Fibrillation After Catheter Ablation</brief_title>
  <official_title>A Randomized Control Study of Catgut Embedding in Acupoint on Treating Persistent Atrial Fibrillation After Catheter Ablation: a Chinese Registry Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Chest Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Chest Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, 2-arm, assessor and statistician blinded, pilot randomized controlled&#xD;
      trial, to evaluate the effect of catgut embedding in acupoints of Neiguan and Zusanli in&#xD;
      reducing early recurrence and improving long-term prognosis in patients with persistent AF&#xD;
      after CA..&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This multi-center, 2-arm, assessor and statistician blinded, pilot randomized controlled&#xD;
      trial will be conducted at two centers in China: Shanghai Chest Hospital; The Second&#xD;
      Affiliated Hospital of Shandong University of traditional Chinese Medicine. Patients with&#xD;
      persistent atrial fibrillation after catheter ablation are 1:1 randomized into group A&#xD;
      (amiodarone hydrochloride tablet + acupoint catgut embedding), group B (amiodarone&#xD;
      hydrochloride tablet). ECG, inflammatory cytokines,AFEQT scale and other indicators are&#xD;
      analyzed the effect of catgut embedding in acupoints of Neiguan and Zusanli in reducing early&#xD;
      recurrence and improving long-term prognosis in patients with persistent AF after CA.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">December 20, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative atrial fibrillation (AF)/atrial flutter (AFL)/atrial tachycardia (AT) recurrence rate</measure>
    <time_frame>12 months after ablation</time_frame>
    <description>at 12 months (AF/AFL/AT recurrence is defined as presence of documented AF/AFL/AT episodes of 30 seconds or longer duration).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative AF recurrence rate</measure>
    <time_frame>up to 12 months after ablation</time_frame>
    <description>AF recurrence is defined as presence of documented AF episodes of 30 seconds or longer duration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TCM symptom score scale</measure>
    <time_frame>up to 12 months after ablation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory index</measure>
    <time_frame>up to 12 months after ablation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AF-specific Atrial Fibrillation Effect on QualiTy-of-life Scale</measure>
    <time_frame>up to 12 months after ablation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Persistent Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amiodarone hydrochloride tablet + acupoint catgut embedding of Neiguan and Zusanli</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Amiodarone hydrochloride tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Amiodarone hydrochloride tablet + acupoint catgut embedding</intervention_name>
    <description>Patients with persistent AF after undergoing catheter ablation take receive acupoint catgut embedding in Neiguan and Zusanli twice after and one month after surgery combined with amiodarone hydrochloride tablets 200mg bid, 1 month; 200mg qd,maintained to 3 months.All patients, who had no signs of recurrence three months after surgery, stopped taking medication.</description>
    <arm_group_label>group A</arm_group_label>
    <arm_group_label>group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amiodarone hydrochloride tablet</intervention_name>
    <description>Patients with persistent AF after undergoing catheter ablation only take amiodarone hydrochloride tablets 200mg bid, 1 month; 200mg qd,maintained to 3 months.All patients, who had no signs of recurrence three months after surgery, stopped taking medication.</description>
    <arm_group_label>group A</arm_group_label>
    <arm_group_label>group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Age between 18 and 80 years old; 2. Persistent AF（lasting no more than 3&#xD;
             years）after catheter ablation; 3. No acupuncture treatment within the previous 6&#xD;
             months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. A history of allergy to acupuncture or amiodarone; 2. Severe heart failure (New&#xD;
             York Heart Association（NYHA）class III or IV); 3. Echocardiographic parameters: left&#xD;
             ventricular ejection fraction &lt; 40%, left atrium diameter &gt; 5.0cm; 4. Severe lung,&#xD;
             liver, kidney disease or other serious primary diseases; 5. Skin allergy to ECG&#xD;
             monitoring electrode patch. 6. The estimated life expectancy of &lt; 1 year.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xiyao Zhu, M.D.</last_name>
    <phone>+8615628783870</phone>
    <email>zhuxiyao940718@163.com</email>
  </overall_contact>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 17, 2021</study_first_submitted>
  <study_first_submitted_qc>November 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2021</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Chest Hospital</investigator_affiliation>
    <investigator_full_name>Xu Liu</investigator_full_name>
    <investigator_title>Professor, deputy director of cardiology department of Shanghai Chest Hospital</investigator_title>
  </responsible_party>
  <keyword>persistent atrial fibrillation after catheter ablation</keyword>
  <keyword>catgut embedding in acupoints</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amiodarone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

